New Drug Product Slideshows

Cosentyx

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ProAir RespiClick

Treatment or prevention of bronchospasm in patients ≥12 years of age with reversible obstructive airway disease. Prevention of exercise-induced bronchospasm in patients ≥12 years of age.

Farydak

Multiple myeloma, in patients who have received at least two prior regimens (including bortezomib and an immunomodulatory agent), in combination with bortezomib and dexamethasone.

Evotaz

HIV-1 infection in combination with other antiretroviral agents.

Prezcobix

In combination with other antiretroviral agents for treatment of HIV-1 infection in adults with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M T74P, L76V, I84V, L89V).

Cresemba

Invasive aspergillosis. Invasive mucormycosis.

Ibrance

In combination with letrozole, for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease.

Saxenda

Adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 (obese), or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, T2DM, dyslipidemia).

New Products

NAMZARIC

  • 7/5/2015
  • Actavis
  • Memantine HCl extended-release, donepezil HCl; 14mg/10mg, 28mg/10mg; capsules.
  • Moderate-to-severe dementia of the Alzheimer's type in patients stabilized on memantine HCl and donepezil HCl.
COSENTYX

COSENTYX

  • 6/28/2015
  • Novartis Pharmaceuticals Corp
  • Secukinumab 150mg/mL; soln for SC inj; and lyophilized pwd for SC inj after reconstitution; preservative-free.
  • Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

PROAIR RESPICLICK

  • 6/21/2015
  • Teva Pharmaceuticals
  • Albuterol sulfate 90mcg/inh; dry pwd for oral inhalation with a dose counter.
  • Treatment or prevention of bronchospasm in patients ≥12 years of age with reversible obstructive airway disease. Prevention of exercise-induced bronchospasm in patients ≥12 years of age.
FARYDAK

FARYDAK

  • 6/14/2015
  • Novartis Pharmaceuticals Corp
  • Panobinostat 10mg, 15mg, 20mg; capsules.
  • Multiple myeloma, in patients who have received at least two prior regimens (including bortezomib and an immunomodulatory agent), in combination with bortezomib and dexamethasone.
EVOTAZ

EVOTAZ

  • 6/7/2015
  • BristolMyers Squibb
  • Atazanavir 300mg, cobicistat 150mg; tablets.
  • HIV-1 infection in combination with other antiretroviral agents. Limitations of use: guide use in treatment-experienced patients by number of baseline primary protease inhibitor resistance substitutions.
PREZCOBIX

PREZCOBIX

  • 5/29/2015
  • Janssen Pharmaceuticals, Inc.
  • Darunavir 800mg, cobicistat 150mg; tabs.
  • In combination with other antiretroviral agents for treatment of HIV-1 infection in adults with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M T74P, L76V, I84V, L89V).

CRESEMBA

  • 5/24/2015
  • Astellas Pharma US, Inc.
  • Isavuconazonium sulfate 186mg capsules; and 372mg/vial lyophilized powder for IV injection after reconstitution; preservative-free.
  • Invasive aspergillosis. Invasive mucormycosis.
IBRANCE

IBRANCE

  • 5/17/2015
  • Pfizer Inc.
  • Palbociclib 75mg, 100mg, 125mg; capsules.
  • In combination with letrozole, for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease.
SAXENDA

SAXENDA

  • 5/10/2015
  • Novo Nordisk
  • Liraglutide [rDNA origin] 6mg/mL; soln for SC inj.
  • Adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 (obese), or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, T2DM, dyslipidemia). Limitations of use: not indicated for type 2 diabetes. Do not use with Victoza, other GLP-1 receptor agonists, or insulin. Effects on cardiovascular morbidity and mortality have not been established. Safety and efficacy with concomitant other weight loss products has not been established. Not studied in patients with history of pancreatitis.
OPDIVO

OPDIVO

  • 5/3/2015
  • BristolMyers Squibb
  • Nivolumab 10mg/mL; per vial; soln for IV infusion after dilution; preservative-free; contains mannitol.
  • Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.
MOVANTIK

MOVANTIK

  • 4/26/2015
  • AstraZeneca Pharmaceuticals
  • Naloxegol 12.5mg, 25mg; tablets.
  • Opioid-induced constipation in adults with chronic non-cancer pain.
GLYXAMBI

GLYXAMBI

  • 4/19/2015
  • Boehringer Ingelheim and Lilly
  • Empagliflozin, linagliptin; 10mg/5mg, 25mg/5mg; tablets.
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in patients with a history of pancreatitis.
LENVIMA

LENVIMA

  • 4/12/2015
  • Eisai Pharmaceuticals
  • Lenvatinib 4mg, 10mg; capsules.
  • Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

SAVAYSA

  • 4/5/2015
  • Daiichi Sankyo
  • Edoxaban 15mg, 30mg, 60mg; tablets.
  • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5–10 days of initial therapy with parenteral anticoagulant. Limitations of use: not for use in NVAF patients with CrCl >95mL/min.
BELSOMRA

BELSOMRA

  • 3/29/2015
  • Merck Co., Inc.
  • Suvorexant 5mg, 10mg, 15mg, 20mg; tablets.
  • Treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
RAPIVAB

RAPIVAB

  • 3/22/2015
  • BioCryst Pharmaceuticals, Inc.
  • Peramivir 10mg/mL; per vial; solution for IV injection after dilution; preservative-free.
  • Treatment of acute uncomplicated influenza in patients who have been symptomatic for ≤2 days. Limitations of use: Efficacy based on predominantly influenza A virus infections; limited number of influenza B virus subjects enrolled. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. Efficacy not established in serious influenza requiring hospitalization.
BLINCYTO

BLINCYTO

  • 3/15/2015
  • Amgen, Inc.
  • Blinatumomab 35mcg; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
  • Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
VIEKIRA PAK

VIEKIRA PAK

  • 3/8/2015
  • AbbVie
  • Ombitasvir/paritaprevir/ritonavir; 12.5mg/75mg/50mg; with dasabuvir 250mg; tablets.
  • Chronic hepatitis C virus (HCV) genotype 1 infection, with or without ribavirin, including those with compensated cirrhosis. Limitations of use: not for use in patients with decompensated liver disease.
XIGDUO XR

XIGDUO XR

  • 3/1/2015
  • AstraZeneca Pharmaceuticals
  • Dapagliflozin, metformin HCl ext-rel; 5mg/500mg, 5mg/1000mg, 10mg/500mg, 10mg/1000mg; tablets.
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ­dapagliflozin and metformin is appropriate. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis.
AKYNZEO

AKYNZEO

  • 2/22/2015
  • Eisai Pharmaceuticals
  • Netupitant, palonosetron (as HCl) 300mg/0.5mg; hard gelatin capsules.
  • Prevention of acute and delayed nausea and vomiting due to initial and repeat courses of chemotherapy, including highly emetogenic chemotherapy.